Dr. Vita Golubovskaya is a Director of Research and Business Development at Promab Biotechnologies leading research of novel anti-cancer immunotherapies including CAR-T cell therapy. She has more than 20 years of experience in cancer research, oncology and immunology. Previously, Dr. Golubovskaya was a Research Associate Professor at Roswell Park Cancer Institute and Research Professor at University of Buffalo, SUNY, Buffalo, NY. She holds Ph.D in Cell Biology from Institute of Cytology, St. Petersburg, Russia. Dr. Golubovskaya authored more than 80 publications, 20 patents and several book chapters. She was awarded Susan Komen Grant for Breast Cancer, NCI NIH and STTR grants. Dr. Golubovskaya served as a Guest Editor in Frontiers in Bioscience, Anti-Cancer Agents in Medicinal Chemistry and Cancers. She is an Active Member of AACR.
Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy.
Cancers Mar, 2016 | Pubmed ID: 26999211
FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells and .
Frontiers in bioscience (Landmark edition) 06, 2017 | Pubmed ID: 28410137
CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth.
Cancers Oct, 2017 | Pubmed ID: 29065481
CAR-T Cell Therapy: From the Bench to the Bedside.
Cancers Oct, 2017 | Pubmed ID: 29088081
GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.
Frontiers in bioscience (Landmark edition) 06, 2018 | Pubmed ID: 29772559
CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth.
Cancers Sep, 2018 | Pubmed ID: 30208593
Generation of CAR-T Cells for Cancer Immunotherapy.
Methods in molecular biology (Clifton, N.J.) , 2019 | Pubmed ID: 30465215
Hypoxia Selectively Impairs CAR-T Cells In Vitro.
Cancers Apr, 2019 | Pubmed ID: 31052261
Transferrin epitope-CD19-CAR-T cells effectively kill lymphoma cells and .
Frontiers in bioscience (Landmark edition) Jan, 2020 | Pubmed ID: 31585889
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유